Claudia Chiodoni

Senior Staff scientist

Fondazione IRCCS Istituto Nazionale dei Tumori
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (37)

Purpose: Novel combinations are required to overcome resistance to immune checkpoint inhibitors in proficient mismatch repair (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). We aimed to determine whether vorbipiprant, a prostaglandin E2 receptor EP4 subtype antagonist, can convert immune-resistant mCRC into a tumor responsive to anti–PD-1 inhibition. Patients and Methods: This phase Ib/IIa prospective, open-label, single-arm trial followed a 3 + 3 dose-escalation and dose-optimization design. A total of 28 patients with chemorefractory pMMR/MSS mCRC were given dose-escalated oral vorbipiprant (30, 90, or 180 mg twice daily), along with biweekly intravenous balstilimab (3 mg/kg), an anti–PD-1 antibody. The primary endpoints included safety and the disease control rate (DCR). Secondary endpoints were the overall response rate, duration of response, progression-free survival, and overall survival. Results: No dose-limiting toxicities were observed. Of the 28 patients, seven (25%) experienced serious adverse events, but only one was attributed to vorbipiprant and one to balstilimab. The trial achieved a DCR of 50% observed across the entire cohort. In the subgroup of patients with liver metastases (n = 12), the DCR was 25%. The overall response rate was 11%, with three patients showing a partial response (median duration of response, 7.4 months). The median progression-free survival was 2.6 months, and the median overall survival was 14.2 months. Translational exploratory analyses suggested that vorbipiprant may boost response to anti–PD-1 in patients with immunogenic tumors. Conclusions: The combination of vorbipiprant and a PD-1 inhibitor (balstilimab) yielded sufficient activity in refractory pMMR/MSS mCRC, which is worthy of confirmation in future clinical trials in biomarker-enriched populations.

Year:

2025

The release of extracellular DNA is a highly conserved mechanism across species. Extracellular traps released by neutrophils (NETs) represent a strategic defensive tool of the organism against pathogens, through their direct entrapment and killing, but also through the immunoadjuvant ability of their components. In this review, we discuss the involvement of NETs in cancer, from tumour initiation to recurrence, touching also on their role in cancer-associated comorbidities. We also discuss the emerging contribution of NETs in resistance to chemotherapy, radiotherapy and, particularly, immunotherapy, because of their suppression of cytotoxic immune responses and remodelling of the tumour microenvironment into an immune-tolerant niche. The therapeutic dilemma lies in whether targeting NETs to restore anti-tumour immunity may compromise the host’s defence against infections, an adverse effect that is far from negligible in patients who are often already immunocompromised. Furthermore, despite their widely recognized pro-tumoral functions, NETs have also been implicated in supporting anti-tumour immunity in specific contexts. The key challenge, therefore, lies in distinguishing between “bad” pro-tumoral NETs and “good” anti-microbial/anti-tumoral NETs, both for identifying reliable biomarkers and for developing more precise NET-based therapeutic targets.

Year:

2025

Jmjd6-mediated ANXA1 secretion promotes M2 macrophage differentiation in vitro and ex vivo. A) Mean fluorescence intensity (MFI) of M1 and M2 markers in BMDM differentiated into M0, M1 and M2.** p

Year:

2025

Effect of Jmjd6 silencing in PyMT41C-cells. A) Real-Time PCR showing the levels of Jmjd6 in PyMT-41C cells transfected with non-targeting siRNA (siCtr) or specific for Jmjd6. Graph is the average of two independent experiments. Two-tailed unpaired t student test was applied to calculate statistical significance. B) Western blot performed on conditioned medium collected from PyMT-41C transfected as in A). Red Ponceau is shown as loading control. C) IF to detect ANXA1 levels and D) lipid droplet formation in cell transfected as in A).

Year:

2025

JMJD6 regulates lipid metabolism in MCF7 cells. A) Immunohistochemistry staining for ANXA1 (brown) combined with Oil red-O staining (pink) for lipid droplets visualization in wild-type MCF7 cells B) Gene set enrichment plot for 'Hallmark of Adipogenesis' found to be significantly downregulated in JMJD6 KO MCF7 cells compared to scramble control. C) List of 'Reactome Pathways' found to be regulated by the genes included in the gene set enrichment pathway of 'Hallmark of Adipogenesis' and present in the DEGs list of JMJD6 KO versus scramble MCF7 cells.

Year:

2025

Effect of JMJD6 KO in ER positive and negative cell lines. A) Western blot showing the expression of JMJD6 and ERα in wild-type, scramble or JMJD6 KO BT474 cells both in mass cultures (Left panel) and in single clones (right panel). Vinculin is shown as loading control. B) Volcano plot showing the most upregulated (red) and downregulated (green) genes between scramble and wild-type (parental) MCF7 (left) and MDA-MB231 (right) cells.

Year:

2025

Purpose: Novel combinations are required to overcome resistance to immune checkpoint inhibitors in proficient mismatch repair (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). We aimed to determine whether vorbipiprant, a prostaglandin E2 receptor EP4 subtype antagonist, can convert immune-resistant mCRC into a tumor responsive to anti–PD-1 inhibition. Patients and Methods: This phase Ib/IIa prospective, open-label, single-arm trial followed a 3 + 3 dose-escalation and dose-optimization design. A total of 28 patients with chemorefractory pMMR/MSS mCRC were given dose-escalated oral vorbipiprant (30, 90, or 180 mg twice daily), along with biweekly intravenous balstilimab (3 mg/kg), an anti–PD-1 antibody. The primary endpoints included safety and the disease control rate (DCR). Secondary endpoints were the overall response rate, duration of response, progression-free survival, and overall survival. Results: No dose-limiting toxicities were observed. Of the 28 patients, seven (25%) experienced serious adverse events, but only one was attributed to vorbipiprant and one to balstilimab. The trial achieved a DCR of 50% observed across the entire cohort. In the subgroup of patients with liver metastases ( n = 12), the DCR was 25%. The overall response rate was 11%, with three patients showing a partial response (median duration of response, 7.4 months). The median progression-free survival was 2.6 months, and the median overall survival was 14.2 months. Translational exploratory analyses suggested that vorbipiprant may boost response to anti–PD-1 in patients with immunogenic tumors. Conclusions: The combination of vorbipiprant and a PD-1 inhibitor (balstilimab) yielded sufficient activity in refractory pMMR/MSS mCRC, which is worthy of confirmation in future clinical trials in biomarker-enriched populations.

Year:

2025

Trial profile and clinical response. Trial profile showing the number of patients screened, the patients enrolled, and, finally, the number of patients discontinued by the treatment groups ( A ). Swimmer plot showing the duration of treatment with vorbipiprant and balstilimab and RECIST overall tumor assessments ( B ). LM, liver metastases; PD, progressive disease. Spider plot showing the tumor burden over time presented as percentage change in the sum of the target lesions ( C ). Waterfall plot reporting treatment response according to PD-L1 CPS ( D ). NA, not assessable. Vorbipiprant dose always combined with the PD-1 inhibitor balstilimab, if not indicated.

Year:

2025

Gene expression signatures, immune cell enrichment and gene expression–based CMS, and association with treatment response. Treeplot depicting the results of hierarchical clustering of enriched terms from GSEA, comparing enriched pathways in patients with PFS 4 months ( A ). Bar plot reporting the results of the Student t test t statistics comparing inflammatory gene expression signature enrichment scores in patients with PFS >4 months vs. those with PFS B ). Heatmap of normalized enrichment scores of immune cell subtypes, comparing patients with PFS 4 months ( C ). DC, dendritic cells; iDC, immature dendritic cells; mDC, mature dendritic cells; MDSC, myeloid-derived suppressor cells; pDC, plasmacytoid dendritic cells; TFG, follicular helper T cells; TGD, gamma-delta T cells; Treg, regulatory T cells. Stacked barplots representing the proportion of patients assigned to gene expression CMS in patients with PFS >4 months ( n = 6) and patients with PFS n = 17; D ).

Year:

2025

In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate the safety and biological effects of cyclic, five-day FMD in combination with standard antitumor therapies. In 101 patients, the FMD was safe, feasible, and resulted in a consistent decrease of blood glucose and growth factor concentration, thus recapitulating metabolic changes that mediate fasting/FMD anticancer effects in preclinical experiments. Integrated transcriptomic and deep-phenotyping analyses revealed that FMD profoundly reshapes anticancer immunity by inducing the contraction of peripheral blood immunosuppressive myeloid and regulatory T-cell compartments, paralleled by enhanced intratumor Th1/cytotoxic responses and an enrichment of IFNγ and other immune signatures associated with better clinical outcomes in patients with cancer. Our findings lay the foundations for phase II/III clinical trials aimed at investigating FMD antitumor efficacy in combination with standard antineoplastic treatments. Significance: Cyclic FMD is well tolerated and causes remarkable systemic metabolic changes in patients with different tumor types and treated with concomitant antitumor therapies. In addition, the FMD reshapes systemic and intratumor immunity, finally activating several antitumor immune programs. Phase II/III clinical trials are needed to investigate FMD antitumor activity/efficacy. This article is highlighted in the In This Issue feature, p. 1

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (25)

Tiziana Triulzi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Daniele Lecis

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

paolo verderio

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Claudio Tripodo

-

ITALY
View details

Milena Perrone

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Lucio Rovati

Chief, Executive Officer

-

ITALY
View details

Elda Tagliabue

Head of Molecular Targeting Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Andrea Vingiani

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Filippo Pietrantonio

Researcher (non-academic)

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

loris de cecco

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Valter D. Longo

-

UNITED STATES
View details

Federica Morano

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Giovanni Fucà

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Sabina Sangaletti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Carlo Pucillo

Full Professor

University of Udine

ITALY
View details

Paolo Manca

Research Scholar

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Valentina Doldi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Elena Jachetti

Researcher (non-academic)

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Mario Paolo Colombo

Head of Department

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Matteo Milani

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Viviana Vallacchi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Roberta Sulsenti

Open University

UNITED KINGDOM
View details

Monica Niger

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Nadia Zaffaroni

Head of Research Unit (Molecular Pharmacology)

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Valeria Cancila

Assistant Professor

University of Palermo

ITALY
View details